Diadexus, Inc. Stock

DDXSQ

US25245P2056

Pharmaceuticals

Delayed OTC Markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-

21-09-17	Diadexus, Inc. Went Out of Business	CI
18-06-08	Motion for Asset Sale Approved for Diadexus, Inc.	CI

Diadexus, Inc. is a diagnostics company. The Company is engaged in developing and commercializing products that deliver healthcare providers with relevant information to assist in the management of patients throughout the course of cardiac disease. Its capabilities include manufacturing, assay development, Food and Drug Administration (FDA) regulatory clearance, and marketing and selling products. Its commercially-available products consist of two FDA-cleared tests to measure Lp-PLA2: the PLAC Test ELISA Kit (the PLAC ELISA Test) and the PLAC Test for Lp-PLA2 Activity (the PLAC Activity Test). Its other products include proADM; proET-1, which aids in predication of heart failure, and proANP, which aids in predication of heart failure. The Company sells its diagnostic products to laboratories and promotes these products to the laboratories' sales representatives, as well as directly to healthcare providers.

Employees

Sector

Pharmaceuticals

More about the company

Stock Market
Stocks
DDXSQ Stock

Stock markets for all

100% Free Registration

Market Cap	49.2K 43.73K 40.54K 36.88K 69.59K 4.67M 70.71K 487K 191K 2.44M 185K 181K 7.77M	P/E 2014	-3.26x	P/E 2015	-1.14x
Enterprise Value	5.29M 4.7M 4.36M 3.97M 7.48M 502M 7.6M 52.39M 20.54M 262M 19.85M 19.43M 835M	EV / Sales 2014	1.05x	EV / Sales 2015	0.77x
Free-Float	100%	Yield 2014 *	-	Yield 2015	-

21-09-17	Diadexus, Inc. Went Out of Business	CI
18-06-08	Motion for Asset Sale Approved for Diadexus, Inc.	CI
18-05-09	Motion for Asset Sale Filed by Diadexus, Inc.	CI
16-07-31	Diazyme Laboratories, Inc. completed the acquisition of operational assets from Diadexus, Inc. (OTCPK:DDXS.Q).	CI
16-07-29	Motion for Asset Sale Approved for Diadexus, Inc.	CI
16-07-28	General Atomics Corp. entered into purchase agreement to acquire operational assets from Diadexus, Inc. (OTCPK:DDXS.Q) for $4.8 million.	CI
16-07-19	Cleveland HeartLab, Inc. cancelled the acquisition of operational assets from Diadexus, Inc. (OTCPK:DDXS.Q).	CI
16-07-07	Motion for Asset Sale Filed by Diadexus, Inc.	CI
16-07-06	Cleveland HeartLab, Inc. agreed to acquire operational assets from Diadexus, Inc. (OTCPK:DDXS.Q) for $7 million.	CI
16-06-13	Diadexus, Inc. Filed for Bankruptcy	CI
16-06-10	Diadexus, Inc. Announces Resignation of Leone Patterson as Chief Financial Office	CI
16-05-23	Diadexus, Sonic Healthcare USA Sign National Agreement for PLAC Activity Test	CI
16-04-29	Diadexus, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2016	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
DIADEXUS, INC.	-.--%	-.--%	-	-	410
ELI LILLY AND COMPANY	+0.43%	+6.59%	+56.57%	+106.64%	1,120B
JOHNSON & JOHNSON	+0.90%	-2.25%	+32.26%	+63.73%	616B
ABBVIE INC.	+0.71%	+3.24%	+24.33%	+91.33%	504B
ROCHE HOLDING AG	-0.13%	+5.98%	+33.66%	+50.18%	367B
MERCK & CO., INC.	+0.52%	+0.24%	+72.13%	+40.11%	360B
NOVARTIS AG	-0.95%	+4.70%	+19.65%	+42.71%	288B
ASTRAZENECA PLC	-1.98%	+3.73%	-0.89%	+10.43%	258B
AMGEN INC.	-0.35%	+4.25%	+44.74%	+52.06%	234B
GILEAD SCIENCES, INC.	-0.75%	+3.32%	+27.18%	+94.07%	194B
Average	-0.16%	+3.25%	+34.40%	+61.25%	394.09B
Weighted average by Cap.	+0.13%	+3.83%	+39.34%	+71.82%

	2014	2015
Net sales	26.11M 23.21M 21.51M 19.57M 36.94M 2.48B 37.53M 259M 101M 1.29B 98M 95.91M 4.12B	17.88M 15.9M 14.73M 13.41M 25.3M 1.7B 25.7M 177M 69.44M 886M 67.12M 65.69M 2.82B
Net income	-8.47M -7.53M -6.98M -6.35M -11.98M -804M -12.17M -83.85M -32.88M -419M -31.78M -31.1M -1.34B	-7.17M -6.37M -5.9M -5.37M -10.14M -680M -10.3M -70.97M -27.82M -355M -26.89M -26.32M -1.13B
Net Debt	-198K -176K -163K -148K -280K -18.79M -285K -1.96M -769K -9.81M -743K -727K -31.26M	5.24M 4.66M 4.32M 3.93M 7.41M 497M 7.53M 51.9M 20.35M 260M 19.67M 19.25M 827M

Diadexus, Inc. Stock

Stocks

DDXSQ

US25245P2056

Pharmaceuticals

Valuation: Diadexus, Inc.

Latest news: Diadexus, Inc.

Diagnostic & Testing Substances Manufacturers

Financials

Company Profile